AstraZeneca invests $445m in Texas to expand manufacturing facility for Lokelma hyperkalaemia treatment. The expansion includes a new building with two production lines, doubling Lokelma output. The drug generated $542m in 2024 and is forecasted to reach $938m in sales by 2031.

The Texas facility, employing over 250 people, is the sole Lokelma supplier to 50+ countries, including the US. AstraZeneca’s $445m investment follows the commencement of construction on a $4.5bn API manufacturing facility in Virginia. These investments are part of AstraZeneca’s $50bn plan to enhance US manufacturing capabilities by 2030.

Global pharmaceutical companies like AstraZeneca, Roche, and GSK are increasing their investments in the US to create jobs and boost manufacturing capabilities. This move aligns with the Trump administration’s goal of reducing reliance on overseas drug production. AstraZeneca’s expansion in Texas reflects a broader trend of big pharma companies focusing on the US market.

Read more at Yahoo Finance: AstraZeneca doubles Lokelma output with $445m Texas plant expansion